Staar Surgical urges stockholders to vote for Alcon transaction

STAAR Surgical Company (STAA) issued an open letter to STAAR stockholders, which read in part, “The Special Meeting of Stockholders to vote on the amended agreement with Alcon (ALC) is just days away. How you vote at the Special Meeting will greatly influence the value of your shares. You have a choice: Vote to approve the Alcon agreement and receive the $30.75 per share cash value it provides, which represents a 74% premium to STAAR’s 90-day Volume Weighed Average Price as of August 4, 2025 or Risk a future where STAAR’s board, management and strategy are greatly influenced by Broadwood Partners, L.P.’s uninformed views about the challenges facing STAAR’s business. Over the past year, Broadwood has significantly increased its ownership in STAAR and now owns more than 30% of STAAR’s outstanding shares. In addition, Broadwood has repeatedly threatened to run an activist proxy contest to remove three of STAAR’s six directors, which would allow Broadwood to obtain disproportionate influence over STAAR without paying any control premium to STAAR’s other stockholders. We believe the choice is clear – and strongly recommend that STAAR stockholders vote “FOR” the Alcon merger on the WHITE proxy card TODAY.”